ALDX Presents Positive Ph3 Data in Allergic Conjunctivitis


Congrats to ALDX on strong Ph3 data in allergic conjunctivitis (AC) not only showing statistical significant area under curve for ocular itch from 10 to 60 minutes, but also met key secondary endpoints of responders with 2 pt improvement in itch score, which appears clinically meaningful. Key Ph3 data for Reproxalap in Uveitis and Sjogren-Larsson Syndrome (SLS) coming later this year, and Ph3 in dry eye disease and likely 2nd Ph3 in AC should be in 2020. Here's a link to Aldeyra's press release with more info on today's readout.

Results were more positive than we expected based on Phase 2 data, but our iron condor options play on 3/12 made $$ between $5.96 and $11.54. Become Amp Core subscriber today and see our options plays in our same-day subscriber-only Twitter feed.

#AmpFree #Q119

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon